Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 08, 2014 19:00 ET | Source: MediciNova, Inc.

MediciNova Receives Feedback From FDA Regarding Study Protocol for Phase 2 Trial of MN-001 (tipelukast) in NASH

LA JOLLA, Calif., Oct. 8, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
October 06, 2014 19:00 ET | Source: MediciNova, Inc.

MediciNova's MN-001 (tipelukast) NASH Abstract Selected for Late-Breaking Session at the 65th Annual AASLD Meeting in Boston

LA JOLLA, Calif., Oct. 6, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
September 29, 2014 19:00 ET | Source: MediciNova, Inc.

Overview of MediciNova's Clinical Trial of MN-166 (ibudilast) in ALS to be Presented at The 13th Annual NEALS Meeting

LA JOLLA, Calif., Sept. 29, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
September 23, 2014 19:00 ET | Source: MediciNova, Inc.

MediciNova Provides Update on Phase 2b Trial of MN-166 (ibudilast) in Progressive MS

LA JOLLA, Calif., Sept. 23, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
September 07, 2014 19:00 ET | Source: MediciNova, Inc.

MediciNova Announces New NIDA Grant for MN-166 (ibudilast) in Opioid Dependence

LA JOLLA, Calif., Sept. 7, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
September 01, 2014 19:00 ET | Source: MediciNova, Inc.

MediciNova to Present Data on MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) During the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF)

LA JOLLA, Calif., Sept. 1, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
August 25, 2014 19:00 ET | Source: MediciNova, Inc.

MediciNova to Initiate Clinical Trial of MN-166 (ibudilast) in ALS

LA JOLLA, Calif., Aug. 25, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
August 18, 2014 19:00 ET | Source: MediciNova, Inc.

MediciNova Announces Positive Interim Results of Phase 2a Study of MN-166 (ibudilast) in Opioid Dependence

LA JOLLA, Calif., Aug. 18, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
August 11, 2014 19:00 ET | Source: MediciNova, Inc.

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Nonalcoholic Fatty Liver Disease

LA JOLLA, Calif., Aug. 11, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
August 05, 2014 07:30 ET | Source: MediciNova, Inc.

MediciNova Announces Positive Results of MN-001 in Advanced NASH Mouse Model; MediciNova Requests a Meeting With FDA

LA JOLLA, Calif., Aug. 5, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...